🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,187 results for “Takeda” Clear

  1. Alisertib

    Takeda

    Acute Myeloid Leukemia

    phase 2 small molecule completed

    1 trial

  2. Alisertib

    Takeda

    Acute Myelogenous Leukemia

    phase 2 small molecule completed

    1 trial

  3. Alisertib (MLN8237)

    Takeda

    Diffuse Large B-Cell Lymphoma

    phase 2 small molecule completed

    1 trial

  4. AskBio009

    Takeda

    Hemophilia B

    phase 2 mab active

    1 trial

  5. Azacitidine

    Takeda

    Myelodysplastic Syndromes

    phase 2 small molecule completed

    2 trials

  6. Azilsartan

    Takeda

    Hypertension

    phase 2 small molecule completed

    2 trials

  7. B-MAD chemotherapy

    Takeda

    Extranodal NK/T-cell Lymphoma

    phase 2 small molecule completed

    1 trial

  8. BAX 888

    Takeda

    Hemophilia A

    phase 2 small molecule completed

    1 trial

  9. BAX69 + infusional 5-FU/LV

    Takeda

    Metastatic Colorectal Cancer

    phase 2 mab terminated

    1 trial

  10. BAX69 Single-Route Arm

    Takeda

    Refractory Ovarian Cancer With Recurrent Symptomatic Malignant Ascites

    phase 2 mab terminated

    1 trial

  11. Blinatumomab

    Takeda

    Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

    phase 2 mab active

    1 trial

  12. Bortezomib

    Takeda

    Recurrent Plasma Cell Myeloma

    phase 2 small molecule active

    1 trial

  13. Bortezomib

    Takeda

    Plasma Cell Myeloma

    phase 2 small molecule active

    1 trial

  14. Bortezomib

    Takeda

    Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)

    phase 2 small molecule completed

    1 trial

  15. Brentuximab Vedotin

    Takeda

    Hodgkin Disease

    phase 2 small molecule active

    2 trials

  16. Brentuximab Vedotin

    Takeda

    Enteropathy Associated T-cell Lymphoma

    phase 2 small molecule completed

    1 trial

  17. Brentuximab Vedotin in Combination with Tislelizumab

    Takeda

    NK/T Cell Lymphoma Nos

    phase 2 small molecule active

    1 trial

  18. Brentuximab vedotin

    Takeda

    Relapsed or Refractory Hodgkin Lymphoma

    phase 2 small molecule completed

    1 trial

  19. BrentuximabVedotin (BV)

    Takeda

    Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  20. Brigatinib

    Takeda

    NSCLC, Stage III

    phase 2 small molecule terminated

    1 trial

  21. Brigatinib

    Takeda

    NSCLC

    phase 2 small molecule active

    1 trial

  22. Brigatinib

    Takeda

    Neurofibromatosis Type 2

    phase 2 small molecule active

    1 trial

  23. Brigatinib

    Takeda

    Lymphoma, Large-Cell, Anaplastic

    phase 2 small molecule completed

    1 trial

  24. Brigatinib

    Takeda

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources